Childhood-Onset Biotin-Responsive Peripheral Motor Neuropathy (COMNB): A Patient Guide
At a Glance
COMNB is a rare inherited SLC5A6-related disorder that can cause childhood motor-nerve weakness. Treatment requires specialist-guided lifelong biotin, pantothenic acid, and alpha-lipoic acid; high-dose biotin must be reported before blood tests because it can distort results.
Childhood-Onset Biotin-Responsive Peripheral Motor Neuropathy (COMNB) is an extremely rare genetic condition that affects the way your child’s cells receive essential nutrients. It is caused by changes in both copies of the SLC5A6 gene, which provides the instructions for building a transporter on the surface of cells [1][2]. This transporter is responsible for pulling three vital nutritional cofactors—biotin, pantothenic acid (Vitamin B5), and alpha-lipoic acid—into the cells to produce energy. When this transporter is impaired, the body’s cells are deprived of these nutrients, even if your child eats a healthy diet [3][4].
The most significant impact of this nutrient deficiency in the COMNB phenotype is on the motor axons, the transmission structures inside nerves that carry movement signals from the brain to the muscles [2]. Without adequate cellular energy, these nerves struggle to function, leading to motor axonal neuropathy [5]. Symptoms typically become apparent around age 10, though age of onset can vary [1]. A child might become progressively weaker, tire more easily during physical activities, or lose motor skills they once had, such as running or climbing stairs [6][2]. Because the condition is exceptionally rare, it often mimics other metabolic disorders, and many families face a long journey before advanced genetic testing confirms the diagnosis [7]. Note that in medical records, this condition may also be called “SLC5A6-related disorder” or “SMVT deficiency.”
The foundation of managing COMNB is a lifelong, specialist-directed “triple supplementation” protocol. Despite the condition’s name, treating with biotin alone is discouraged; there is evidence that high-dose biotin monotherapy can compete with the other missing nutrients at the transporter, potentially worsening the underlying biochemical imbalance [8][3]. Instead, metabolic specialists prescribe targeted doses of all three nutrients—biotin, pantothenic acid, and lipoic acid—to bypass the defective transporter and support the cells [5][1]. Based on clinical case reports, this treatment aims to stabilize the disease and can lead to meaningful improvements in strength, though established nerve damage heals slowly and may only partially reverse [2][9].
Living with COMNB requires a strong partnership with a metabolic care team, particularly regarding medical testing. The high-dose biotin therapy required for treatment disrupts specific laboratory platforms (streptavidin-biotin immunoassays), which can cause blood tests to show dangerously incorrect results—such as falsely low troponin (hiding a heart issue) or falsely altered thyroid levels [10][11][12]. Families must inform every doctor and laboratory about the high-dose biotin regimen so they can use alternative testing methods, and must never alter or pause the vitamin protocol without direct supervision from their metabolic specialist [13][14].
In this guide
5 chapters
Understanding Your Child's Diagnosis: COMNB and SLC5A6
Learn what COMNB and SLC5A6-related disorder mean, how nutrient transport affects motor nerves, and why lifelong biotin, B5, and lipoic acid therapy matters.
Genetic Testing and the Path to a Diagnosis
Learn how COMNB is diagnosed through SLC5A6 genetic testing, biotinidase activity, metabolic markers, fibroblast assays, and testing for look-alike disorders.
Symptoms and the Disease Spectrum: COMNB vs. SMVTD
Learn how SLC5A6-related COMNB and SMVTD differ, including symptoms, onset age, metabolic crisis warning signs, and when to seek emergency care for your child.
Treatment: The Triple Supplementation Protocol
Learn how COMNB treatment combines biotin, pantothenic acid, and alpha-lipoic acid, why biotin alone may be risky, and how specialists monitor children.
Building Your Care Team and Long-Term Monitoring
Learn how COMNB care teams monitor motor function, growth, and lab markers, and how families can prevent high-dose biotin from distorting urgent blood tests.
Common questions in this guide
What is COMNB?
What symptoms can COMNB cause in a child?
Why does COMNB treatment use three nutrients instead of biotin alone?
Can high-dose biotin change my child’s blood-test results?
How is COMNB diagnosed?
Can treatment repair nerve damage caused by COMNB?
Get notified when new evidence is published on peripheral motor neuropathy, childhood-onset, biotin-responsive.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Novel missense variants cause intermediate phenotypes in the phenotypic spectrum of SLC5A6-related disorders.
Utsuno Y, Hamada K, Hamanaka K, et al.
Journal of human genetics 2024; (69(2)):69-77 doi:10.1038/s10038-023-01206-5.
PMID: 38012394 - 2
Genome sequencing enables diagnosis and treatment of SLC5A6 neuropathy.
Riley LG, Sabui S, Said HM, et al.
European journal of human genetics : EJHG 2024; (32(8)):947-953 doi:10.1038/s41431-024-01641-8.
PMID: 38816490 - 3
Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells.
Uchida Y, Ito K, Ohtsuki S, et al.
Journal of neurochemistry 2015; (134(1)):97-112 doi:10.1111/jnc.13092.
PMID: 25809983 - 4
Novel biallelic variants expand the SLC5A6-related phenotypic spectrum.
Holling T, Nampoothiri S, Tarhan B, et al.
European journal of human genetics : EJHG 2022; (30(4)):439-449 doi:10.1038/s41431-021-01033-2.
PMID: 35013551 - 5
SLC5A6 Mutations in Axonal Sensorimotor Polyneuropathy Patients Concurrent With Sodium Dependent Multivitamin Transporter Deficiency and Improved Effects by Multivitamin Therapy.
Pi BK, Lee AJ, Nam SH, et al.
Journal of the peripheral nervous system : JPNS 2025; (30(2)):e70030 doi:10.1111/jns.70030.
PMID: 40396389 - 6
Genotype/phenotype correlations in AARS-related neuropathy in a cohort of patients from the United Kingdom and Ireland.
Bansagi B, Antoniadi T, Burton-Jones S, et al.
Journal of neurology 2015; (262(8)):1899-908 doi:10.1007/s00415-015-7778-4.
PMID: 26032230 - 7
Genetic defect of the sodium-dependent multivitamin transporter: A treatable disease, mimicking biotinidase deficiency.
Schwantje M, de Sain-van der Velden M, Jans J, et al.
JIMD reports 2019; (48(1)):11-14 doi:10.1002/jmd2.12040.
PMID: 31392107 - 8
Sodium-dependent multivitamin transporter deficiency caused by novel SLC5A6 mutations: a clinical case and personalized mice model study.
Priymak AV, Averina OA, Novikova MA, et al.
Frontiers in cell and developmental biology 2026; (14()):1925753 doi:10.3389/fcell.2026.1925753.
PMID: 42920491 - 9
A novel SLC5A6 homozygous variant in a family with multivitamin-dependent neurometabolic disorder: Phenotype expansion and long-term follow-up.
Montomoli M, Vetro A, Tubili F, et al.
European journal of medical genetics 2023; (66(8)):104808 doi:10.1016/j.ejmg.2023.104808.
PMID: 37391029 - 10
A survey-based study of physician practices regarding biotin supplementation.
Waqas B, Wu A, Yim E, Lipner SR
The Journal of dermatological treatment 2022; (33(1)):573-574 doi:10.1080/09546634.2020.1770178.
PMID: 32419559 - 11
Comprehensive assessment of biotin interference in immunoassays.
Li J, Wagar EA, Meng QH
Clinica chimica acta; international journal of clinical chemistry 2018; (487()):293-298 doi:10.1016/j.cca.2018.10.013.
PMID: 30296442 - 12
Susceptibility of Cardiac Troponin Assays to Biotin Interference.
Frame IJ, Joshi PH, Mwangi C, et al.
American journal of clinical pathology 2019; (151(5)):486-493 doi:10.1093/ajcp/aqy172.
PMID: 30715102 - 13
A new case of sodium-dependent multivitamin transporter defect occurring as a life-threatening condition responsive to early vitamin supplementation and literature review.
Van Vyve FX, Mercier N, Papadopoulos J, et al.
Molecular genetics & genomic medicine 2024; (12(2)):e2388 doi:10.1002/mgg3.2388.
PMID: 38407570 - 14
Best practices in mitigating the risk of biotin interference with laboratory testing.
Bowen R, Benavides R, Colón-Franco JM, et al.
Clinical biochemistry 2019; (74()):1-11 doi:10.1016/j.clinbiochem.2019.08.012.
PMID: 31473202
This page is for informational purposes only and does not constitute medical advice. Your child’s metabolic specialist should guide supplementation, testing, and emergency or sick-day decisions, and every clinician should know about high-dose biotin.